---

Antibiotics Safe During Lactation & Postpartum Depression

---

Part 1: Antibiotics Safe During Lactation

General Principles

• Relative infant dose (RID): the fraction of maternal dose an infant receives via milk — generally safe if <10%
• Oral bioavailability in the infant (drugs with poor GI absorption, e.g. IV vancomycin, pose minimal risk)
• Infant age and health (preterm or renally compromised infants need extra caution)
• Common minor side effects in the infant: loose stools, colic, diarrhoea — inconvenient but not a reason to stop breastfeeding

Safe Antibiotic Classes (First-Line Choices)

Antibiotics Requiring Caution

Antibiotics to Avoid

• Chloramphenicol (systemic) — risk of bone marrow suppression
• Dapsone — haemolytic anaemia risk in infants
• Linezolid — insufficient data, potential toxicity

Lactational Mastitis

---

Part 2: Postpartum Depression (PPD)

Definition & Epidemiology

• Formally defined as a major depressive episode within 4 weeks of delivery (DSM-5 uses "peripartum onset" — symptoms from pregnancy through 1 month postpartum)
• Affects ~10–15% of mothers; rates triple among adolescent and inner-city mothers
• Completed suicide is a leading cause of maternal mortality; infanticide, more often associated with postpartum psychosis (PPP), is also a devastating outcome
• Up to 1 in 5 women remain depressed for a year or longer if untreated

DSM-5 Diagnostic Criteria (Major Depressive Episode + Peripartum Onset)

1. Depressed mood most of the day, nearly every day
2. Markedly diminished interest or pleasure
3. Appetite/weight changes
4. Insomnia or hypersomnia
5. Psychomotor agitation or retardation
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive guilt
8. Difficulty concentrating
9. Recurrent thoughts of death or suicidal ideation

Risk Factors

• Prior history of depression or mood disorder (most significant risk)
• Discontinuing antidepressants prior to pregnancy (relapse rate 68% vs. 26% in those continuing medication)
• Single motherhood, domestic violence, low income, adolescent age
• History of depression during previous pregnancies
• Rapid postpartum hormone decline (allopregnanolone, estrogen, progesterone)

Screening

• Edinburgh Postnatal Depression Scale (EPDS) — widely validated; recommended at OB and primary care visits postpartum
• Screening recommended for all postpartum women at 6-week visit and beyond

Treatment

1. Non-pharmacological (mild-moderate PPD)

• Psychotherapy: Cognitive Behavioural Therapy (CBT) and Interpersonal Therapy (IPT) — first-line for mild cases
• Digital health interventions: meta-analyses (PMID 37330123) show benefit for postpartum depression/anxiety
• Postpartum exercise: meta-analysis (PMID 39500542) demonstrates significant reduction in depression scores
• Psychoeducation, social support, sleep hygiene

2. Pharmacological (moderate-severe PPD)

3. Novel FDA-Approved Agent: Brexanolone (Zulresso®)

• Mechanism: Positive allosteric modulator of GABA-A receptors; synthetic analogue of allopregnanolone (a progesterone metabolite that drops sharply post-delivery — implicated in PPD etiology)
• Route: Continuous IV infusion over 60 hours in an inpatient setting
• Adverse effects: Excessive sedation, sudden loss of consciousness, hypoxia — patient must be monitored continuously; supervised interaction with the baby during treatment is required
• Limitation: High cost and inpatient requirement limit broad use
• "Currently, brexanolone is the only medication specifically FDA-approved for the treatment of postpartum depression." — Goodman & Gilman's

4. Zuranolone (Zurzuvae®) — 2023 Approval

• Oral neurosteroid (GABA-A modulator), same class as brexanolone
• 14-day course taken orally — avoids inpatient requirement
• FDA-approved August 2023 for PPD

5. Role of Antidepressants During Breastfeeding

• Sertraline is the antidepressant of choice when breastfeeding — lowest relative infant dose among SSRIs
• Women who needed antidepressants during pregnancy should not discontinue postpartum; the postpartum period is high risk for relapse

Key Clinical Pearls

• Do not stop breastfeeding simply because antibiotics are needed — the vast majority are compatible, and the benefits of breastfeeding far outweigh the minor GI effects in the infant
• PPD is underdiagnosed — screen proactively with EPDS; symptoms can overlap with normal postpartum exhaustion
• Do not confuse PPD with postpartum blues (transient, resolves within 2 weeks, no treatment needed) or postpartum psychosis (rare, psychiatric emergency requiring hospitalisation)
• For women with a history of severe depression, continuing antidepressants through pregnancy and postpartum is strongly preferred over dose tapering

---

---

Causes of Thrombocytopenia

• <150,000/μL → thrombocytopenia
• 20,000–50,000/μL → increased risk of post-traumatic bleeding
• <20,000–30,000/μL → spontaneous mucocutaneous bleeding; petechiae, ecchymoses
• <10,000/μL → frequently lethal (CNS hemorrhage risk)

---

Pathophysiologic Classification

Key clue: In destructive thrombocytopenias, bone marrow shows compensatory megakaryocyte hyperplasia. In production failure, megakaryocytes are reduced or absent.

---

I. Decreased Production

A. Generalized Bone Marrow Dysfunction (Pancytopenia)

• Aplastic anemia — congenital (Fanconi anemia, dyskeratosis congenita) or acquired (idiopathic, drugs, radiation, viral)
• Marrow infiltration — leukemia, lymphoma, multiple myeloma, metastatic carcinoma (breast, prostate, lung)
• Myelodysplastic syndrome (MDS) — clonal stem cell disorder; ineffective hematopoiesis
• Myelofibrosis

B. Selective Impairment of Platelet Production

• Drugs: alcohol (direct marrow toxin), thiazide diuretics, cytotoxic chemotherapy
• Infections: measles virus, HIV (HIV directly suppresses megakaryocyte development and survival — thrombocytopenia is one of the most common hematologic manifestations of AIDS; incidence has fallen sharply with antiretroviral therapy)

C. Ineffective Megakaryopoiesis (Platelets produced but abnormal/destroyed intramedullarily)

• Megaloblastic anemia (B12 or folate deficiency)
• Paroxysmal nocturnal hemoglobinuria (PNH)
• Iron deficiency (in severe cases)
• Copper deficiency

D. Congenital/Inherited Thrombocytopenias

• Congenital amegakaryocytic thrombocytopenia (CAMT) — c-Mpl mutations
• Bernard-Soulier syndrome — giant platelets, GPIb/IX/V complex deficiency
• Wiskott-Aldrich syndrome — small platelets, immunodeficiency, eczema
• MYH9-related disorders (May-Hegglin anomaly, Fechtner syndrome) — giant platelets, leukocyte inclusions
• Thrombocytopenia with absent radii (TAR)
• Fanconi anemia

---

II. Increased Destruction

A. Immunologic (Immune-Mediated)

1. Immune Thrombocytopenic Purpura (ITP)

• Mechanism: IgG autoantibodies against platelet membrane glycoproteins GPIIb/IIIa or GPIb/IX (detected in ~80% of cases) → opsonized platelets cleared by splenic macrophages
• Chronic ITP: Women aged 20–40 years; insidious onset; splenomegaly absent but spleen is the primary destruction site and antibody production site; splenectomy achieves complete remission in >2/3 of patients
• Acute ITP: Children; post-viral; self-limited

2. Drug-Induced Immune Thrombocytopenia

• Heparin (see HIT below — most important)
• Quinidine / quinine — hapten mechanism; antibody formed against drug-platelet complex
• Sulfa compounds, trimethoprim-sulfamethoxazole
• Acetaminophen, ibuprofen, naproxen
• Ampicillin, piperacillin, vancomycin, linezolid
• Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)
• Cimetidine

3. Heparin-Induced Thrombocytopenia (HIT)

• Occurs in 3–5% of patients after 1–2 weeks of unfractionated heparin
• Mechanism: IgG antibodies against platelet factor 4 (PF4)–heparin complex → immune complexes bind platelet Fcγ receptors → massive platelet activation → thrombosis (paradox: thrombocytopenia + thrombosis, not just bleeding)
• Both venous and arterial thromboses occur (stroke, MI, DVT/PE, limb ischemia)
• Management: Stop heparin immediately; use alternative anticoagulants (argatroban, fondaparinux)
• Risk is lower with LMWH than unfractionated heparin

4. Alloimmune Thrombocytopenia

• Neonatal alloimmune thrombocytopenia (NAIT): Maternal IgG antibodies against fetal platelet antigens (typically HPA-1a); cross placenta → fetal/neonatal thrombocytopenia (risk of intracranial hemorrhage)
• Post-transfusion purpura: Severe thrombocytopenia 5–10 days after transfusion; anti-HPA-1a antibodies destroy host platelets

5. Secondary Immune Thrombocytopenia

• SLE (systemic lupus erythematosus) — anti-platelet antibodies + anti-phospholipid antibody syndrome
• Antiphospholipid antibody syndrome
• Rheumatoid arthritis
• Lymphoproliferative disorders (CLL, non-Hodgkin lymphoma)
• Evans syndrome — autoimmune hemolytic anemia + immune thrombocytopenia (direct Coombs positive)

6. Infection-Related Immune Thrombocytopenia

• HIV — multi-factorial: immune complex-mediated, autoantibodies, megakaryocyte suppression
• Infectious mononucleosis (EBV)
• Cytomegalovirus (CMV)
• Hepatitis C (HCV) — also associated with hypersplenism from cirrhosis
• Rubella
• H. pylori — eradication can improve ITP

---

B. Non-Immunologic (Consumptive) Destruction

1. Thrombotic Microangiopathies (TMA)

2. Disseminated Intravascular Coagulation (DIC)

• Systemic activation of coagulation → consumption of platelets and clotting factors
• Causes: sepsis, trauma, malignancy, obstetric emergencies (abruptio placentae, amniotic fluid embolism), major burns
• Labs: ↓ platelets, ↓ fibrinogen, ↑ PT/PTT, ↑ D-dimer, ↑ FDPs; schistocytes on smear

3. Other Non-Immune Destruction

• Cardiopulmonary bypass / extracorporeal circuits — mechanical shear stress
• Intravascular catheters / IABP
• Septicemia / systemic inflammatory response syndrome — platelet activation by thrombin and proinflammatory cytokines
• Hemophagocytosis (HLH) — macrophage ingestion of platelets; infection-triggered or malignancy-associated
• Aortic stenosis — acquired vWF degradation (Heyde syndrome)

---

III. Splenic Sequestration

• Normally the spleen holds ~30% of total platelet mass; with massive splenomegaly this can rise to 80–90%
• Causes: portal hypertension (cirrhosis, schistosomiasis), storage diseases (Gaucher disease), lymphoma, myeloproliferative neoplasms
• Platelet counts rarely fall below 30,000–50,000/μL from sequestration alone unless combined with reduced production

---

IV. Dilutional Thrombocytopenia

• Massive transfusion with packed red cells (which lack platelets) and colloid resuscitation
• Stored blood contains essentially no functional platelets after 24–48 hours
• Clinical rule: significant dilutional thrombocytopenia typically after transfusion of >10 units pRBCs

---

V. Pregnancy-Related Thrombocytopenia

---

VI. Other / Miscellaneous Causes

• Malaria — splenic sequestration + immune destruction; P. falciparum causes the most severe thrombocytopenia
• Dengue fever — one of the commonest infectious causes worldwide; direct viral suppression + immune-mediated
• COVID-19 — complement activation, cytokine storm, vaccine-induced immune thrombocytopenia with thrombosis (VITT)
• Post-COVID VITT — anti-PF4 antibodies (similar to HIT mechanism) after adenoviral vector COVID vaccines
• Nutritional deficiencies — B12, folate, copper (impaired megakaryopoiesis)
• Hypothyroidism / hyperthyroidism
• Pseudothrombocytopenia — EDTA-dependent in vitro platelet clumping (~2% of cases reported as low platelet counts); always check peripheral smear to exclude before workup

---

Diagnostic Approach Summary

Low platelet count on CBC
        ↓
Examine peripheral blood smear
  ├── Platelet clumps → PSEUDOTHROMBOCYTOPENIA (re-check in citrate tube)
  ├── Schistocytes → TMA (TTP/HUS/DIC)
  ├── Hypersegmented neutrophils → Megaloblastic anemia
  ├── Blast cells → Leukemia/marrow infiltration
  └── Normal morphology → ITP, drug-induced, gestational, hypersplenism
        ↓
History: Drugs? Heparin? Pregnancy? Infection? Autoimmune symptoms?
        ↓
Bone marrow biopsy if production failure suspected
  ├── ↓ Megakaryocytes → Production failure (aplasia, infiltration)
  └── ↑ Megakaryocytes → Peripheral destruction/sequestration

---

---

Stepwise Algorithm for Tourette Disorder (TD)

---

Diagnostic Criteria (DSM-5)

1. Multiple motor tics AND ≥1 vocal (phonic) tic — not necessarily concurrent
2. Tics present for >1 year (with possible waxing-and-waning; no tic-free period >3 consecutive months)
3. Onset before age 18 years
4. Not attributable to substances or another medical condition (e.g. Huntington disease, post-viral encephalitis)

Key features: Tics are semi-voluntary (preceded by a premonitory urge); can be suppressed for short periods; wax and wane in frequency and pattern. Tics typically peak in severity between ages 10–12 and improve in ~50% by early adulthood.

---

Essential Pre-Treatment Assessment

"Behavioral difficulties are more strongly associated with psychosocial functioning than the presence of tics itself" — Bradley & Daroff's Neurology

---

The Stepwise Algorithm

---

STEP 1 — Psychoeducation & Watchful Waiting

• Educate patient, family, teachers about the natural history (tics often lessen with age; not voluntary; not a sign of poor upbringing)
• Reduce tic-triggering stress, fatigue, excitement
• Advise teachers: do not punish tic behavior; allow private spaces for tic release
• AAN 2019 Guideline (reaffirmed April 2025): treatment is not always necessary; initiate only when tics cause distress, functional impairment, injury, or social difficulties
• Monitor periodically — reassess need for further treatment

If tics are mild and not functionally impairing → continue watchful waiting with reassessment

---

STEP 2 — Behavioral Therapy (First-Line Active Treatment)

CBIT — Comprehensive Behavioral Intervention for Tics (gold standard)

• Expanded form of Habit Reversal Training (HRT)
• Components:
  1. Awareness training — identify premonitory urge and tic
  2. Competing response training — substitute an incompatible, inconspicuous movement when urge arises
  3. Function-based assessment — identify contexts that worsen tics
  4. Relaxation training
  5. Social support engagement
• Evidence: Level A (strongest) per AAN
• 8–10 weekly sessions; gains maintained at follow-up

ERP — Exposure and Response Prevention

• Habituate to premonitory urge without performing tic
• Evidence: strong, particularly favored in European guidelines
• Alternative when CBIT not available or preferred

HRT alone — core technique within CBIT; effective as standalone

2024 data (Wang et al.): CBT/HRT showed significantly greater reduction in tic severity than clonidine transdermal patches at 24-week follow-up in children.

If behavior therapy is unavailable, refused, or insufficient → proceed to pharmacotherapy

---

STEP 3 — Tier 1 Pharmacotherapy

Alpha-2 Adrenergic Agonists ← First pharmacological choice

• Effective in approximately 50% of patients
• Side effects: sedation, hypotension, dry mouth, rebound hypertension on abrupt cessation
• Particularly preferred when ADHD is comorbid (treat both conditions simultaneously)

Topiramate — alternative Tier 1 agent

• Low dose (25–200 mg/day); some evidence for tic reduction
• Useful when antipsychotics are to be avoided
• Side effects: cognitive dulling, weight loss, renal stones

---

STEP 4 — Tier 2 Pharmacotherapy

Atypical Antipsychotics ← Second-line; preferred over typicals due to side-effect profile

Aripiprazole is now the most widely recommended first antipsychotic by both European and North American guidelines due to its superior tolerability profile compared to FGAs.

---

STEP 4b — VMAT2 Inhibitors (Alternative Tier 2)

---

STEP 5 — Tier 3 / Treatment-Resistant Pharmacotherapy

Typical (First-Generation) Antipsychotics

Emerging Agents

• Ecopipam (D1 receptor antagonist) — Phase III trial results awaited (2024); may offer tic suppression without EPS
• Cannabis-based agents (cannabidiol, THC) — limited evidence; may benefit refractory adult TS

Botulinum Toxin Injections

• AAN Recommendation C (Level C evidence)
• For localized, bothersome, simple motor tics in adolescents and adults
• Most useful for: eye blinking, neck/head tics, shoulder tics, laryngeal tics (severe vocal tics)
• Duration of effect: 12–16 weeks per injection; repeat treatment required
• Side effect for laryngeal injection: hypophonia

---

STEP 6 — Treatment of Comorbidities (Parallel Track — Always Address)

---

STEP 7 — Refractory / Severe TS: Deep Brain Stimulation (DBS)

• Age typically ≥18 years (rarely younger in exceptional cases)
• Definite DSM-5 diagnosis of TS
• Severe, disabling tics refractory to adequate trials of ≥3 medications and behavioral therapy
• Stable psychiatric status; no active suicidality
• Absence of significant structural brain abnormality
• Informed consent; multidisciplinary team assessment

1. Centromedian-parafascicular thalamus (CM-Pf) — most commonly used; better efficacy data
2. Globus pallidus internus (GPi) — second most used; motor and non-motor territories
3. Anterior limb of internal capsule (ALIC) — less evidence

---

Summary Flowchart

CONFIRMED TOURETTE DISORDER
        │
        ▼
STEP 1: Psychoeducation + Watchful Waiting
  └── Mild, no functional impairment → Monitor; no further Rx needed
        │
        ▼ [Moderate tics / functional impairment / distress]
STEP 2: Behavioral Therapy (CBIT or ERP) ← FIRST-LINE ACTIVE TREATMENT
  └── If unavailable / inadequate
        │
        ▼
STEP 3: Alpha-2 Agonists (Guanfacine or Clonidine)
        + Topiramate (alternative)
  └── Especially if ADHD comorbid
  └── If inadequate after adequate trial
        │
        ▼
STEP 4: Atypical Antipsychotics
        Aripiprazole (PREFERRED, FDA-approved) 
        ± Risperidone / VMAT2 inhibitors
        │
        ▼ [Refractory]
STEP 5: Haloperidol / Pimozide (with ECG monitoring)
        Botulinum toxin (for localized tics)
        Ecopipam (emerging)
        │
        ▼ [Severely refractory adults]
STEP 6: Deep Brain Stimulation
        CM-Pf thalamus or GPi
        
PARALLEL TRACK (All Steps): Treat ADHD, OCD, Anxiety, Depression

---

• Individualize treatment — tic severity, comorbidities, patient/family preference, drug availability
• Treat the most impairing symptom first (often the comorbidity, not the tic itself)
• "Least intrusive, smallest risk" principle — behavioral before pharmacological, alpha-2 agonists before antipsychotics
• Periodically reassess need for continued medication (many patients improve spontaneously in adulthood)
• Do not use methylphenidate reflexively in ADHD comorbidity — may exacerbate tics

---

---

Complex Tics in a 17-Year-Old Female: Onset at Age 7 — Indian Context

---

Clinical Context & Why This Case Is Distinctive

---

Step 1: Define the Tic Type — Simple vs. Complex

Simple Tics

Complex Tics (This Patient)

Key distinction: Complex tics appear intentional but are NOT voluntary. They follow a premonitory urge and are briefly suppressible. This is critical to convey to the family, school, and patient.

---

Step 2: DSM-5 Classification

---

Step 3: Causes of Complex Tics

A. Primary Tic Disorders (Most Common)

1. Tourette Disorder / Gilles de la Tourette Syndrome

• Most common cause of childhood-onset complex motor + vocal tics
• Prevalence ~0.5–1% in children; male predominance 3:1
• No single causative gene identified; complex inheritance
• Pathophysiology: dopaminergic dysfunction + cortico-striatal-thalamo-cortical (CSTC) circuit dysregulation
• Tics peak ~age 10–12, often improve by late adolescence/adulthood

2. Persistent (Chronic) Motor or Vocal Tic Disorder

• Motor tics only OR vocal tics only, persisting >1 year

---

B. Secondary / Organic Causes — Must Be Excluded

PANDAS is especially important in India: Group A beta-hemolytic streptococcal (GABHS) infection is common; rheumatic fever remains prevalent; antineuronal antibodies from GABHS trigger OCD-like symptoms + tics with dramatic, abrupt onset — "Sydenham chorea, OCD, tics, emotional lability, ADHD all described following GABHS infection" (Kaplan & Sadock's). India also has high rates of RF/rheumatic heart disease, making this differential critical.

---

Step 4: Comprehensive Assessment

History (Structured)

Physical Examination

Standardized Rating Scales

Investigations

---

Step 5: India-Specific Clinical Profile Data

• Tics manifest after 5–6 years and are most severe in adolescents
• Tics are genetic (53% twin concordance) but genetic loci unknown
• CBIT recommended as initial treatment but availability is very limited in India → pharmacotherapy is the practical first-line

---

Step 6: Management — Tailored for This Patient (17F, India)

Parallel Track: Always Address Comorbidities First

---

TIER 1: Psychoeducation (All Patients — Mandatory First Step)

• Explain TS/complex tic disorder to patient, parents, teachers
• Clarify tics are not voluntary, not behavioral, not a result of poor parenting
• Address cultural stigma — in India, complex tics (especially coprolalia if present) may be attributed to possession, behavioral problem, or psychiatric instability
• Explain natural history — may improve after adolescence
• Coordinate with school: private space for tic release; no punishment
• Teacher psychoeducation via referral letter or school visit
• Connect with Indian support organizations (Tourette India Network)

---

TIER 2: Behavioral Therapy (Preferred Active Treatment)

• In India: limited availability — refer to child psychologists/psychiatrists trained in HRT/CBIT in major urban centers (NIMHANS Bangalore, AIIMS Delhi, CMC Vellore)
• Components: Awareness training + Competing response training + Functional intervention
• ERP (Exposure and Response Prevention): Alternative behavioral approach

---

TIER 3: Pharmacotherapy

First Choice: Alpha-2 Agonists

Second Choice: Atypical Antipsychotics

VMAT2 Inhibitors (Alternative)

• Tetrabenazine / Deutetrabenazine: Effective for tics; risk of depression — use cautiously in this age group; access may be limited/costly in India

Third-line: Typical Antipsychotics

• Haloperidol 0.5–5 mg/day — used in India; high risk of EPS in young patients
• Pimozide — QTc monitoring mandatory; ECG required before and during use; largely falling out of use

Topiramate

• 25–200 mg/day; modest tic reduction; useful if antipsychotics contraindicated
• Available in India; affordable

Botulinum Toxin Injections

• For localized, particularly bothersome motor tics (eye blinking, neck tics, shoulder tics)
• Available in major Indian centers; specialist administration

---

TIER 4: Treating Comorbidities

• Penicillin prophylaxis (secondary prevention of GABHS) — monthly benzathine penicillin injections or daily oral penicillin
• Immunotherapy: IVIG or plasmapheresis for severe PANDAS exacerbations (specialist referral)
• Treat underlying rheumatic carditis if present

---

TIER 5: For Severely Refractory Cases (Age ≥18, Specialist-Only)

• Deep Brain Stimulation (DBS): CM-Pf thalamus or GPi; available at select centers in India (NIMHANS, AIIMS, Apollo)
• Requires multidisciplinary team; strict patient selection criteria
• At 17, DBS would not yet be considered; reassess at 18+ if refractory

---

Monitoring & Follow-Up

---

Prognosis in This Patient

---

Referral Network in India

---

---

PUO & Recurrent Fever: Tests and Causes in a 40-Year-Old Indian Female

---

Definition

• Temperature >38.3°C (101°F) on multiple occasions
• Duration ≥3 weeks
• No diagnosis after ≥1 week of intensive investigation (or a standard basic workup)

---

Why Female Age 40 is a Distinct Clinical Profile

---

Causes of PUO — Epidemiological Profile for India

Global Data (Harrison's 22E, 2025 — Table 22.1)

Asia has a lower undiagnosed rate than Europe and a higher infectious fraction — strongly relevant to India.

---

Category 1: INFECTIONS (Most Common in India — ~42–66%)

A. Mycobacterial ← Top Priority in India

B. Tropical / Vector-borne Infections ← India-Specific Priority

C. Bacterial / Pyogenic

D. Viral

E. Fungal / Parasitic

---

Category 2: NON-INFECTIOUS INFLAMMATORY DISEASES (NIID) — ~10–20% in India

HIGH PRIORITY in a 40-Year-Old Indian Female:

---

Category 3: MALIGNANCIES — ~9–21% in India

---

Category 4: RECURRENT FEVER — Additional Differential

Hereditary Periodic Fever Syndromes (consider if recurrent, episodic, with symptom-free intervals)

Other Recurrent Fever Causes (India-Relevant)

---

Investigations — Stepwise Workup

Tier 1: First-Line Investigations (ALL patients)

---

Tier 2: Second-Line / Targeted by Clinical Clues

---

Tier 3: Advanced / Specialist Investigations

---

Recurrent Fever — Additional Specific Tests

---

Diagnostic Algorithm for 40-Year-Old Indian Female

DOCUMENTED FEVER >38.3°C × ≥3 WEEKS WITHOUT CLEAR DIAGNOSIS
                    │
                    ▼
STEP 1: DETAILED HISTORY & PHYSICAL EXAMINATION
  ├── Travel history; animal contact; dairy exposure; TB contact
  ├── Joint pains, rashes, oral ulcers, sicca symptoms → Autoimmune
  ├── Night sweats, weight loss, lymphadenopathy → TB / Lymphoma
  ├── Recurrent? Symptom-free intervals? → Periodic fever syndrome
  ├── Fever pattern (quotidian = Still's; tertian = malaria; Pel-Ebstein = lymphoma)
  └── Drug history (stop all non-essential drugs for 72 hours)
                    │
                    ▼
STEP 2: TIER 1 INVESTIGATIONS (ALL patients)
  CBC + differential | Peripheral smear | ESR | CRP | LFT | RFT
  Blood cultures ×3 | Urine R/E + culture | Chest X-ray
  Malarial smear ×3 + RDT | Widal + Typhoid IgM
  IGRA/Mantoux | ANA | Serum ferritin | Dengue NS1 + serology
                    │
              ┌─────┴──────┐
        Clues found?      No clues
              │                │
              ▼                ▼
    TARGETED TIER 2        TIER 2 BROAD
    (by clinical context)  CECT Chest/Abdomen/Pelvis
              │            (most diagnostically impactful)
              ▼                │
   Autoimmune: ANA panel,      │
   dsDNA, ANCA, CK           ───┤
   Infections: Scrub typhus,    │
   Leishmania, Brucella, HIV   │
   Malignancy: CECT + LDH      │
                    │
                    ▼
STEP 3: TIER 3 (No diagnosis after Tier 1+2)
  Bone marrow biopsy | Lymph node biopsy | FDG-PET/CT
  Liver biopsy | Echocardiography | Endoscopy
                    │
                    ▼
  Still no diagnosis → Periodic fever workup (gene testing)
                     → Consider empirical therapeutic trial
                     → Reassess in 4–6 weeks (many resolve spontaneously)

---

Female-Specific Additional Priorities at Age 40

---

India-Specific Key Points

1. TB is the single most important cause — extrapulmonary and miliary TB can present without respiratory symptoms; bone marrow biopsy culture is the gold standard for miliary TB
2. Scrub typhus is now recognized across all Indian states (not just Himalayan/northeastern India); must be included in all febrile workup; ELISA IgM is preferred over Weil-Felix
3. SLE in India presents at a younger age than in the West; more aggressive renal and CNS involvement; ANA + anti-dsDNA are mandatory in any 40-year-old Indian female with PUO
4. Adult-onset Still's disease — serum ferritin >10,000 μg/L is the key diagnostic clue; quotidian fever + salmon rash + arthritis
5. Takayasu arteritis — young Indian women; assess for unequal pulses, BP difference between arms, carotid bruits; MR angiography
6. Visceral leishmaniasis — consider in all febrile patients from Bihar, UP, Jharkhand, West Bengal with prolonged fever + splenomegaly + pancytopenia + failure to respond to antibiotics; rK39 rapid test has >95% sensitivity in India
7. CECT chest/abdomen/pelvis is the most impactful single investigation in PUO (Indian and South Asian data from multiple studies)
8. FDG-PET/CT: increasingly available at major Indian centres (AIIMS Delhi, Tata Memorial Mumbai, PGIMER Chandigarh, NIMHANS Bangalore); most sensitive for occult infection, inflammation, and malignancy

---

---

Long-Term Pharmacotherapy for Methamphetamine Dependence (Methamphetamine Use Disorder)

---

Overview: The Fundamental Challenge

"No pharmacologic treatments currently produce consistent, clinically meaningful decreases in stimulant use." — Kaplan & Sadock's Synopsis of Psychiatry

"There is currently no FDA-approved medication for methamphetamine use disorder." — ADAPT-2 trial (NEJM 2021); reaffirmed in J Clin Psychiatry 2025

---

Pathophysiology — Basis for Drug Targets

1. Reversing dopamine transporter (DAT) — massive dopamine efflux into synapse
2. Blocking dopamine, norepinephrine, and serotonin reuptake
3. Depleting dopamine stores from vesicles (via VMAT2 reversal)
4. Prolonged downregulation of D2 receptors — the neurobiological basis of anhedonia, craving, and protracted withdrawal

• Dopaminergic hypofunction in striatum and prefrontal cortex
• Persistent anhedonia, depressed mood, cognitive impairment
• Strong craving — especially in the protracted abstinence period (weeks to months)
• High relapse rates (neurobiological, not just behavioural)

• Reducing euphoria (dopamine receptor modulation)
• Reducing withdrawal dysphoria (norepinephrine/dopamine support)
• Reducing craving (opioid system modulation)
• Substitution/agonist approaches (prescribed stimulants)
• Treating comorbid psychiatric disorders (depression, ADHD, anxiety)

---

Evidence Summary Table

---

Drug-by-Drug Evidence

---

1. Extended-Release Naltrexone (XR-NTX) + Extended-Release Bupropion (XR-BUPN)

• Naltrexone: μ-opioid receptor antagonist → blocks reward/euphoria of MA; opioid system is involved in dopamine-mediated reward
• Bupropion: norepinephrine + dopamine reuptake inhibitor → reduces withdrawal dysphoria; stimulant-like properties attenuate MA craving

• Design: Double-blind, placebo-controlled, multicenter RCT (NIDA Clinical Trials Network); 403 adults with moderate-to-severe MUD
• Regimen: XR-NTX 380 mg IM every 3 weeks + XR-BUPN 450 mg/day PO × 12 weeks
• Primary outcome: ≥3 of 4 urine screens negative for MA at end of 6-week stage
• Results: Response 13.6% (treatment) vs 2.5% (placebo); treatment effect = +11.1 percentage points (p<0.001)
• Adverse events: GI disorders, tremor, malaise, hyperhidrosis, anorexia; serious AEs in 3.6%

• Participants on XR-NTX + XR-BUPN showed additional 9.2% improvement in stage 2 (weeks 7–12) above stage 1 gains
• Total 12-week increase in MA-negative urine probability: +27.1% (vs +11.4% in placebo; difference = 15.8%, p=0.006)
• Implication: Continued treatment beyond 6 weeks drives further reduction; longer-term treatment likely beneficial

• Early reduction in depressive symptoms with NTX+BUPN at 2–4 weeks predicted subsequent reduction in MA use
• Supports the model that treating withdrawal dysphoria mediates reduction in use

• Absolute response rate remains low (13.6%) — most patients still use MA on this regimen
• Optimal duration of long-term treatment unknown — ongoing Phase 3 trial (NCT06233799, NIDA, 2024–2027)
• NOT FDA-approved for this indication (as of May 2026)
• Contraindications to naltrexone: hepatic impairment, concurrent opioid use; to bupropion: seizure risk, anorexia/bulimia, MAOI use

---

2. Mirtazapine

• 2 placebo-controlled RCTs (n=180); cisgender men and transgender women
• Mirtazapine likely results in small reduction in MA use at 12 weeks (RR=0.81; 95% CI: 0.63–1.03)
• No improvement in treatment retention or depression symptom severity
• No serious adverse events
• Evidence certainty: moderate (GRADE)
• 2025 RCT data (Rush et al., Drug Alcohol Depend 2025, PMID 40580890): Mirtazapine reduces hypothetical methamphetamine demand in humans — supporting further study

• Men who have sex with men (MSM) with MA use
• Transgender women
• Patients with prominent MA withdrawal insomnia and anxiety
• When bupropion + naltrexone not tolerated or contraindicated

---

3. Prescribed Psychostimulants (Agonist/Substitution Approach)

• 10 RCTs (n=561); methylphenidate 54–180 mg/day (7 trials) and dextroamphetamine 60–110 mg/day (3 trials)
• PPs significantly decreased end-point craving (SMD = -0.29; p<0.05)
• Reduction in MA-positive urine did not reach significance in primary analysis (RR=0.93; p=0.09) but was significant after removing high-bias studies (RR=0.89; p=0.04)
• Higher doses and longer duration (≥20 weeks) → better retention and outcomes
• No effect on withdrawal, depression, self-reported use, or retention in primary analysis

• All are Schedule II controlled substances — significant diversion and misuse risk
• Not approved for MUD — prescribing off-label requires careful monitoring and clinical judgment
• Evidence strongest in patients with less severe MUD
• Best rationale when patient also has co-occurring ADHD (which is common in stimulant users)
• Regular urine drug screening and pill counts mandatory

---

4. Bupropion Alone

• Multiple RCTs showing modest benefit specifically in non-daily or less severe MA users
• Not effective in moderate-to-severe dependence when used alone (Kaplan & Sadock's Synopsis)
• Better used as part of the combination with naltrexone (ADAPT-2)

---

5. Naltrexone Alone

• Jayaram-Lindström et al. (2008): RCT showing some benefit for amphetamine dependence
• Modest effect on craving and use reduction in less severe MUD
• Best use: combination with bupropion (ADAPT-2)

• Oral naltrexone: 50 mg/day (poor adherence — major limitation)
• XR-injectable naltrexone (Vivitrol® 380 mg IM q3–4 weeks) — preferred for long-term adherence

---

6. Agents with No Proven Long-Term Benefit

---

Special Situations in Long-Term Management

Comorbid ADHD (Common)

• Prevalence of ADHD in MUD patients is significantly elevated
• Treating ADHD with prescribed stimulants (lisdexamfetamine, methylphenidate) is defensible and may reduce MA use
• Start low; monitor for diversion and misuse
• Non-stimulant: atomoxetine or guanfacine are safer alternatives with less diversion potential

Comorbid Depression (Very Common — Protracted Withdrawal)

• MA withdrawal causes protracted dysphoria for weeks to months
• Bupropion XR addresses both depression and MA withdrawal dysphoria simultaneously
• SSRIs for comorbid depression (note: do not reduce MA use directly)
• Mirtazapine for depression + insomnia + MA craving (especially in MSM)

Comorbid Methamphetamine-Induced Psychosis (Acute Phase)

• Antipsychotics (risperidone, olanzapine, aripiprazole, haloperidol) for acute psychosis — NOT for long-term dependence treatment
• Psychosis typically resolves within days to weeks of abstinence
• Persistent psychosis beyond 1 month: consider schizophrenia spectrum diagnosis

Comorbid Opioid Use Disorder

• Buprenorphine or methadone maintenance as the opioid treatment
• Naltrexone (XR-injectable) cannot be used in active opioid users (precipitates withdrawal)
• Meta-analysis (Chan et al., 2020, PMID 32861136): evaluated medications for stimulant + opioid use disorders; buprenorphine maintenance associated with reduced stimulant use in co-occurring disorders

Sleep Disturbances (Near-Universal in Long-Term MUD)

• Protracted insomnia is a major relapse trigger
• Mirtazapine 30 mg at bedtime — addresses insomnia + craving
• Systematic review (Bourtin et al., Drug Alcohol Depend 2026, PMID 41855890): reviewed pharmacological strategies for sleep disturbances in stimulant use disorders

---

Long-Term Treatment Framework

METHAMPHETAMINE USE DISORDER (Moderate–Severe)
              │
              ▼
STEP 1: Assessment & Stabilisation
  ├── Severity (DSM-5: mild/moderate/severe)
  ├── Comorbidities: ADHD, depression, psychosis, opioid use
  ├── Social support, motivation, treatment setting
  └── Safety: acute psychosis, suicidality, cardiovascular status
              │
              ▼
STEP 2: Psychosocial Foundation (ALWAYS — Non-negotiable)
  ├── Contingency Management (strongest behavioural evidence)
  ├── Cognitive Behavioural Therapy (CBT)
  ├── Motivational Enhancement Therapy (MET)
  └── 12-step programmes / mutual support
              │
              ▼
STEP 3: Pharmacotherapy (Adjunctive — Off-label)

  FIRST CHOICE (Moderate-Severe MUD):
  ├── XR-Naltrexone (380 mg IM q3wk) + XR-Bupropion (450 mg/day PO)
  │   [ADAPT-2 trial, NEJM 2021; best available evidence]
  │
  ALTERNATIVE/ADJUNCTIVE:
  ├── Mirtazapine 30 mg nocte
  │   (especially MSM, transgender women, insomnia, anxiety)
  │
  ├── Prescribed Stimulant (if co-occurring ADHD confirmed):
  │   Lisdexamfetamine > Methylphenidate XR > Dextroamphetamine
  │
  └── Treat comorbid conditions:
      ADHD → stimulant or atomoxetine
      Depression → bupropion, mirtazapine, SSRI
      Psychosis → antipsychotic (time-limited)
              │
              ▼
STEP 4: Long-Term Monitoring
  ├── Urine drug screens (periodic, random)
  ├── Psychiatric comorbidity reassessment
  ├── Metabolic monitoring (antipsychotics if used)
  ├── LFTs if naltrexone used
  ├── Cardiac monitoring (bupropion: QTc; stimulants: BP/HR)
  └── Duration: no established endpoint — reassess every 3–6 months

---

Regulatory Status & Pipeline (May 2026)

---

Clinical Bottom Line

1. No drug is FDA-approved for MUD — all pharmacotherapy is adjunctive to psychosocial treatment
2. XR-Naltrexone + XR-Bupropion is the best-evidenced combination (NEJM 2021); absolute response rates are modest but statistically significant and clinically meaningful in a refractory disorder
3. Mirtazapine has moderate-certainty evidence for small reduction in MA use, especially in MSM — a useful clinical option particularly for insomnia and anxiety
4. Prescribed stimulants (methylphenidate, lisdexamfetamine) modestly reduce craving; best justified when co-occurring ADHD is confirmed
5. Longer treatment duration (≥20 weeks for stimulants; ≥12 weeks for naltrexone+bupropion) improves outcomes — this is critically important for long-term management
6. Treat comorbidities aggressively — ADHD, depression, insomnia, and anxiety are relapse triggers and are pharmacologically actionable
7. Contingency management remains the strongest behavioural intervention and should underpin all pharmacotherapy

---

---

Speech & Language Milestones: 7-Year-Old Male Child

---

Developmental Context

---

Domain 1: Speech Sounds (Articulation & Phonology)

Expected at Age 7

Late-Developing Sounds Timeline (Context)

A 7-year-old boy who still misarticulates /r/ is at the boundary of normal — this is the last sound to fully master. However, persistent errors on /s/, /l/, or earlier sounds at age 7 warrant referral for evaluation.

Phonological Awareness (Completed by Age 7)

• Reading decoding
• Spelling
• Written language development

---

Domain 2: Receptive Language (What the Child Understands)

---

Domain 3: Expressive Language (What the Child Says)

Sentence Structure & Grammar

Vocabulary

Expressive Content & Discourse

---

Domain 4: Phonological Awareness & Literacy (Age 7 = 2nd Grade)

At age 7, the shift is from decoding (learning to read) to reading for comprehension (reading to learn). Persistent reading difficulties at this age should prompt evaluation for dyslexia.

---

Domain 5: Social/Pragmatic Communication

---

Cumulative Milestone Summary Table

---

Full Developmental Trajectory (Birth → 7 Years)

---

Red Flags at Age 7 — When to Refer

---

Assessment Tools Used in Clinical Practice

---

Important Points for Male Children

• Boys typically develop slightly later than girls in language milestones, though the difference is small and often clinically insignificant by school age
• Speech sound errors are more common and persist longer in boys
• Stuttering is 4× more common in boys; predominantly male
• Boys are at higher risk for reading difficulties and specific language impairment
• A 7-year-old boy with persistent articulation errors or language delays should not be dismissed as "boys mature later" — formal evaluation is warranted

---